← Back to Search

Janus kinase (JAK) inhibitor

Tofacitinib for Ulcerative Colitis (TRIUMPH Trial)

Q: What medical ailments is Tofacitinib 10 MG [Xeljanz] most frequently prescribed for?

<p>Tofacitinib 10 MG [<a href="https://www.withpower.com/clinical-trials/xeljanz">Xeljanz</a>] is a common prescription for juvenile <a href="https://www.withpower.com/clinical-trials/arthritis">arthritis</a>. Additionally, it may be beneficial to individuals who are methotrexate impenitent or have had an inadequate response to traditional treatments.</p>

Phase 2

Waitlist Available

Led By Neeraj Narula, MD

Research Sponsored by McMaster University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 52 weeks

Awards & highlights

TRIUMPH Trial Summary

This trial will study whether tofacitinib can help treat ulcerative colitis in hospitalized patients.

Eligible Conditions

Ulcerative Colitis Acute

TRIUMPH Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 52 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~52 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Clinical response at day 7

Secondary outcome measures

1. Percentage of patients who achieve clinical remission at day 7, and weeks 12, 26, and 52 (Partial Mayo score < 2, with no subscore >1)

Comparison of absolute change from baseline endoscopic Mayo score at week 26

Comparison of number of patients with severe colitis based on histology who are able to achieve histological improvement (mild or inactive colitis) at week 26

+6 more

TRIUMPH Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment armExperimental Treatment1 Intervention

Tofacitinib 10mg PO BID

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

McMaster UniversityLead Sponsor

890 Previous Clinical Trials

2,605,408 Total Patients Enrolled

4 Trials studying Ulcerative Colitis

870 Patients Enrolled for Ulcerative Colitis

University of ManitobaOTHER

596 Previous Clinical Trials

199,335 Total Patients Enrolled

4 Trials studying Ulcerative Colitis

2,206 Patients Enrolled for Ulcerative Colitis

University of British ColumbiaOTHER

1,422 Previous Clinical Trials

2,468,249 Total Patients Enrolled

8 Trials studying Ulcerative Colitis

2,042 Patients Enrolled for Ulcerative Colitis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What hazards are associated with ingesting Tofacitinib 10 MG [Xeljanz]?

"Despite the lack of evidence for its efficacy, Tofacitinib 10 MG [Xeljanz] has sufficient safety data to be scored a 2 on our team's scale."

Answered by AI

What is the overall enrollment size of this clinical trial?

"Indeed, according to the available clinicaltrials.gov records, this medical trial is actively enrolling participants. First posted on June 1st 2021 and most recently updated on June 8th, it seeks 26 individuals at a single site."

Answered by AI

What medical ailments is Tofacitinib 10 MG [Xeljanz] most frequently prescribed for?

"Tofacitinib 10 MG [Xeljanz] is a common prescription for juvenile arthritis. Additionally, it may be beneficial to individuals who are methotrexate impenitent or have had an inadequate response to traditional treatments."

Answered by AI

Are there any additional research studies involving Tofacitinib 10 MG [Xeljanz] that have been conducted?

"Presently, there are 34 active trials researching the effectiveness of Tofacitinib 10 MG [Xeljanz], 7 of which have reached Phase 3. Although Shanghai is the primary location for these experiments, 662 other sites worldwide are also involved in this research endeavour."

Answered by AI

Is this clinical research still enrolling participants?

"Correct. According to clinicaltrials.gov, this medical experiment, which was posted on June 1st 2021, is currently enlisting patients for participation. A total of 26 participants need to be enrolled from one centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management

2021. "Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04925973.

All > Ulcerative Colitis > Colitis